摘要:
A method for predicting a subject's risk factors for ACE-related disorders includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject.
摘要:
Diagnostic and prognostic methods, compositions, assays, and kits useful for predicting the phenotype of subjects who have, or are at risk of developing, a mental disorder. The methods also include predicting the prognostic outcome of a subject's mental disorder as well as the subject's responsiveness to drug treatments for the mental disorder. The methods and kits include determining the allelic status of polymorphisms in the MAOA, TPH2 and DRD2 genes.
摘要:
A method for predicting a subject's risk factors for ACE-related disorders includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject.
摘要:
A method for predicting a subject's risk factors for CYP2C9-related disorders includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject.
摘要:
A method for predicting a subject's risk factors for CYP3A4-related disorders includes detecting the allelic status of a SNP in a nucleic acid sample of the subject.
摘要:
A method for predicting a subject's risk factors for CYP3A4-related disorders includes detecting the allelic status of a SNP in a nucleic acid sample of the subject.
摘要:
A non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects, and insufficient to block substantial central effects, of the opioid agonist in the subject. Such formulations, and methods of using same, may also deter diversion, inhibit peripheral effects, and reduce addiction liability.
摘要:
A method for screening G protein coupled receptors is provided in which G protein coupled receptors that are constitutively active are determined, such as by measuring receptor phosphorylation agonist independent signalling. When a G protein coupled receptor is found to be regulated by constitutive activity, then assay systems may be set up to classify test compounds as agonists, neutral antagonists, or negative antagonists with respect to G protein coupled receptor signalling and phosphorylation. Such determinations and screening are useful for selecting new pharmaceuticals potentially useful in treating disease states mediated by G protein coupled receptors, with applications including treatments in conjunction with narcotic analgesia.